European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Home
/
update
/
details

Surfix Diagnostics Collaborates with Dutch Partners to Validate Colon Cancer Screening

NextEdge Admin

11 Jul 2024

1 min 10 sec

Surfix Diagnostics announced a collaboration with the Netherlands Cancer Institute (NKI) and CRCbioscreen to advance colorectal cancer screening methods. This initiative, named PHOBICCS and supported by a Health~Holland public-private partnership grant, leverages Surfix's photonic diagnostic platform alongside novel biomarkers identified by NKI.

Previously, CRCbioscreen and NKI researchers introduced the MultitargetFIT test, based on a three-protein assay, demonstrating superior performance compared to traditional fecal immunochemical testing. The current focus involves exploring new biomarkers identified by NKI, which exhibit specific molecular profiles associated with both cancers and high-risk precursor lesions prone to progressing into cancerous conditions.

The collaboration aims to enhance early detection capabilities through innovative diagnostic approaches, potentially offering more accurate and effective screening tools for colorectal cancer.